| External factors: | 19i |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Urothelial carcinoma |
| Experiment: | Flow cytometry//MTT assay//SA-β-gal activity assay//Cell morphological analysis |
| Description: | Based on the results from the MTT assays, in the following experiments, cells were usually treated with 2 μM 19i or with 2.5 μM SAHA. Treatment with 2 μM 19i impaired the clonogenic potential of UC cells comparably to treatment with the pan-HDACi SAHA. This was also the case for HEK-293 cells, but HBLAK again were less sensitive .Efficacious concentrations of 19i elicited an increased fraction of cells in the G2/M phase in UC cells and in the non-urothelial HEK-293 cells.Over time, cells became larger and flatter, indicative of cellular senescence .Indeed, some 19i-treated cells, especially from the VM-CUB1 cell line, stained positive for senescence-associated β-galactosidase. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: